DU145

[1] DU145, PC3, and LNCaP are considered to be the standard prostate cancer cell lines used in therapeutic research.

[1] The DU145 cell line was derived from a central nervous system metastasis, of primary prostate adenocarcinoma origin, removed during a parieto-occipital craniotomy of a 69-year-old, White, male.

[4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).

[5] NEK6 inhibition is a potential treatment for CRPC due to its role as an essential protein kinase in the mitotic cell cycle.

Although specific pathways remain unclear, deactivating the NEK6 gene is able to decrease clonogenic capacity, proliferation, cell viability, and mitochondrial activity.